永久性粒子前列腺近距离放疗后前列腺特异性抗原长期稳定性及失败预测因素
研究评估低剂量率前列腺近距离放疗后前列腺特异性抗原(PSA)长期稳定性及PSA缓慢上升但未达生化失败标准时的预测因素。2,339例低中危前列腺癌患者接受碘-125粒子植入,中位随访89个月,86%患者PSA稳定,6%上升,8%生化失败。未接受雄激素剥夺治疗者中,PSA最低值和60个月PSA是失败最强预测因素(OR 20.6和18.3)。
要点
- 86%患者PSA稳定在手术消融水平,生化失败率8%,PSA上升仅6%且多无临床意义。
- 未接受雄激素剥夺治疗者中,PSA最低值和60个月PSA是失败最强预测因素(OR 20.6和18.3,均P<0.0001)。
- 接受雄激素剥夺治疗且PSA上升者中,60个月PSA(OR 53.9)和T分期(OR 0.25)可预测失败。
核心结论
- 近距离放疗治愈率高,86%患者PSA稳定在手术消融水平。
- PSA上升发生率低(6%)且常无临床意义。
研究设计与样本
- 回顾性分析前瞻性数据库,纳入1998至2010年接受碘-125近距离放疗的低或中危前列腺癌患者2,339例,至少随访3年,49.7%接受6个月雄激素剥夺治疗。
- 生化结果分为PSA稳定、PSA上升(≥0.2 ng/ml且近2年升高≥0.1 ng/ml)或生化失败(最低值+2 ng/ml)。
- 采用多因素分析识别失败预测因素并构建逻辑回归模型。
主要发现
- 中位随访89个月(范围37至199),2,004例(86%)PSA稳定(最低值0.03 ng/ml,60个月时0.04 ng/ml),145例(6%)PSA上升(最低值0.16 ng/ml,60个月时0.29 ng/ml),190例(8%)生化失败(最低值0.51 ng/ml,P<0.001)。
- 未接受雄激素剥夺治疗者中,PSA最低值和60个月PSA是失败最强预测因素(OR 20.6和18.3,均P<0.0001),模型灵敏度85%、特异度98%,在82例中预测失败8例(9.8%)。
- 接受雄激素剥夺治疗且PSA上升者中,60个月PSA(OR 53.9,P<0.0001)和T分期(OR 0.25,P=0.0008)为预测因素,模型在56例中预测生化失败30例(54%),灵敏度85%、特异度93%。
- 两个预测模型预期整个队列治愈率达90%。
关键数值与推荐
- 生化失败定义为PSA最低值+2 ng/ml。
- PSA上升定义为PSA≥0.2 ng/ml且近2年内升高≥0.1 ng/ml。
- 未接受雄激素剥夺治疗者预测模型:PSA最低值OR 20.6(P<0.0001),60个月PSA OR 18.3(P<0.0001)。
- 接受雄激素剥夺治疗且PSA上升者预测模型:60个月PSA OR 53.9(P<0.0001),T分期OR 0.25(P=0.0008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Defining biochemical failure as nadir + 2 may overestimate cure after radiotherapy. We assessed long-term prostate specific antigen stability after low dose rate prostate brachytherapy and predictors of biochemical failure when prostate specific antigen was slowly rising below the nadir + 2 ng/ml threshold. MATERIALS AND METHODS: A total of 2,339 patients with low or intermediate risk prostate cancer received 125iodine brachytherapy from 1998 to 2010 with a minimum 3-year followup. In addition, 49.7% of the patients received 6 months of androgen deprivation. Clinical, dosimetric and prostate specific antigen data were retrieved from a prospective database. Biochemical results were classified as stable or rising prostate specific antigen (0.2 ng/ml or greater and increased 0.1 ng/ml or greater during the preceding 2 years), or biochemical failure (defined as nadir + 2). Multivariate analysis was done to identify predictors of failure used to create logistic regression models. RESULTS: At a median followup of 89 months (range 37 to 199) prostate specific antigen was stable (nadir 0.03 ng/ml and at 60 months 0.04 ng/ml) in 2,004 patients (86%) and rising (nadir 0.16 ng/ml and at 60 months 0.29 ng/ml) in 145 (6%) while biochemical failure (nadir 0.51 ng/ml, p <0.001) was noted in 190 (8%). When there was no prior androgen deprivation therapy, the prostate specific antigen nadir and prostate specific antigen at 60 months were the strongest predictors of failure (OR 20.6 and 18.3, respectively, each p <0.0001). The logistic regression model had 85% sensitivity and 98% specificity, and predicted failure in 8 of 82 men (9.8%). A second model was created for the group with androgen deprivation therapy and rising prostate specific antigen using the predictive factors prostate specific antigen at 60 months (OR 53.9, p <0.0001) and T stage (OR 0.25, p = 0.0008). This model predicted biochemical failure in 30 of 56 men (54%) with 85% sensitivity and 93% specificity. The 2 predictive models yield an anticipated 90% cure rate in the entire cohort. CONCLUSIONS: Brachytherapy is highly curative with stable prostate specific antigen at a surgical ablation level in 86% of patients. Rising prostate specific antigen is rare at a 6% incidence and often innocuous.
引用
- Tetreault-Laflamme A, Crook J, Hamm J, et al. Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy. J Urol. 2017. PMID: 28827105. doi:10.1016/j.juro.2017.07.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。